Actavis announces European launch of Quetiapine

Actavis Group has announced the launch of its new anti-psychotic medicine Quetiapine – a generic equivalent of AstraZeneca's Seroque product.

Targeted for the treatment of conditions including depression, bipolar disorders and schizophrenia, the drug will be delivered by the global pharmaceutical firm in the UK, Germany, Italy, Ireland, the Netherlands and Romania upon the expiration of the Seroque patent in Denmark.

Available in a variety of strengths, ranging from 25 to 300 mg, the product is also to be launched in Sweden on April 1st.

Quetiapine is manufactured at the company's facility in Malta.

Founded in 1956, the firm specialises in the development and manufacture of a range of medicines across many forms, including tablets, injectibles, suppositories, powders, oral liquids and solids.

At present, Actavis operates in more than 40 countries and employs in excess of 10,000 members of staff, placing it among the largest generic pharmaceutical providers in the world.